Biomarin Pharmaceutical (BMRN) Gross Profit (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Gross Profit came in at $571.2 million in Q1 2026, down 3.77% YoY from $593.6 million in Q1 2025, and down 4.62% on a QoQ basis from $598.9 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Gross Profit (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Gross Profit data on file, last reported at $571.2 million in Q1 2026.
- Quarterly Gross Profit fell 3.77% year-over-year to $571.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 5.88% YoY) and the FY2025 annual result came in at $2.5 billion, up 10.12% from the prior year.
- Gross Profit fell to $571.2 million in Q1 2026, from $598.9 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $675.3 million in Q2 2025 to a low of $389.1 million in Q3 2022.
- A 5-year average of $519.3 million and a median of $523.7 million in 2024 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit soared 30.03% — and 2026, when it declined 3.77%.
- Tracing BMRN's Gross Profit over 5 years: stood at $390.9 million in 2022, then soared by 30.03% to $508.3 million in 2023, then grew by 20.24% to $611.2 million in 2024, then decreased by 2.02% to $598.9 million in 2025, then decreased by 4.62% to $571.2 million in 2026.
- The last three Gross Profit figures came in at $571.2 million (Q1 2026), $598.9 million (Q4 2025), and $636.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 786.91 Mn |
| Jun 30, 2026 | 786.91 Mn |
| Mar 31, 2026 | 571.21 Mn |
| Mar 31, 2026 | 571.21 Mn |
| Dec 31, 2025 | 598.86 Mn |
| Dec 31, 2025 | 598.86 Mn |
| Sep 30, 2025 | 636.05 Mn |
| Sep 30, 2025 | 636.05 Mn |
| Jun 30, 2025 | 675.32 Mn |
| Jun 30, 2025 | 675.32 Mn |
| Mar 31, 2025 | 593.59 Mn |
| Mar 31, 2025 | 593.59 Mn |
| Dec 31, 2024 | 611.17 Mn |
| Dec 31, 2024 | 611.17 Mn |
| Sep 30, 2024 | 557.28 Mn |
| Sep 30, 2024 | 557.28 Mn |
| Jun 30, 2024 | 581.57 Mn |
| Jun 30, 2024 | 581.57 Mn |
| Mar 31, 2024 | 523.65 Mn |
| Mar 31, 2024 | 523.65 Mn |